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Introduction
Mental illness has once been considered in the past stages of 
human civilization, as conditions associated with mystical causes 
hence, rituals based on religion and superstition resorts were 
accepted  methods to treat these diseases [1]. Socrates, Hipocrates, 
and Galeno for instance, believed in four essential elements that 
controlled human behavior blood, bile, black bile, and phlegm. 
This belief persisted through the middle ages and conducted 
doctor’s practices in order to equilíbrate those four humors.
ABSTRACT
Introduction: Mental health treatment has varied in the last century; however, the impact of these new therapeutical 
options is little-known.
Objectives: To evaluate the impact of treatments for mental health diseases along the last decades.
Methodology: retrospective, descriptive case-report study. Medical records of patients admitted to a Mental 
Health Institution in Buenos Aires, Argentina were evaluated over 7 decades. Variables analyzed were: age, sex, 
diagnosis, time of hospital stay, number of re-hospitalizations, drugs available per decade, cost of drug, cost of 
hospitalizations.
Results: Hospitalization average lenght of stay was 6.33 months, with 3.18 readmissions per patient. In the 21st 
century it was detected a reduction in the length of hospitalization (4.66 months) and an increase in the number 
of hospitalizations (4.3 hospitalizations/patient). The number of drugs prescribed was 5.14 per patient (1.6 in the 
1950s and 7.22 in the last decade). During 1950s, the most prescribed drugs were lithium and chlorpromazine, in 
the ’60s haloperidol; in the ‘70s benzodiazepines, haloperidol, and amitriptyline; in the ‘80s and ‘90s fluoxetine, 
sertraline, and BZD; from the 2000s paroxetine, risperidone, and pregabalin were added to the earlier drugs; 
and in the current decade new antipsychotics (olanzapine, ziprasidone, quetiapine or lurasidone), antiepileptics 
(lamotrigine) were included. Although diagnoses were maintained over time (schizophrenia, psychosis, bipolar 
disorder, dementia, depression) in the last decade, 27.7% of the hospitalized patients had dual pathology 
(addiction+other mental illness). Cost of drugs prescribed increased >9 times, while the cost of hospitalization 
increased >4 times in the last decade compared to the second half of the 20th century.
Conclusion: Although new drugs to treat severe mental disorders reduced side effects associate to treatment, its 
efficacy did not improve neither the duration of the hospital stay nor in the number of re-hospitalizations along the 
past 70 years; while cost of new drugs increased 9 times.
*Correspondence:
Dr. Gustavo H. Marin, Pharmacology Department, National 
University of La Plata, Argentina, Tel: +54 221 4216932.
Received: 25 October 2020; Accepted: 11 November 2020
Volume 3 | Issue 6 | 2 of 5Int J Psychiatr Res, 2020
The belief that mental alteration was a choice of individuals 
associated with their abnormal behavior, led doctors to use physical 
restrictions such as straitjackets or punishments as treatments to 
try to restore the balance of "the 4 humors" [1].
Mental illness were for centuries seen as a source of shame, 
concealment, and social stigma for families with members affected 
by this type of disease. Because of this reason, religion also played 
a key role in mental treatment where priests’ duty replaced medical 
care isolating mentally ill people in churches and monasteries. 
These ideas continued until the year 1800 when French and 
English doctors adopted the concept of “moral treatment” in the 
care of these patients, based on isolation, rewards and punishments 
actions against disruptive behavior [2].
In the early 20th century, contemporary doctors strongly disagree 
with these thoughts and adopted new ideas in order to substitute 
the type of care proposed for these patients. One of the leading 
figures of that siecle was Sigmund Freud, which developed the 
theory of psychoanalysis, installing practices that encouraged 
patients to talk about their problems in order to open a door to their 
unconscious mind and repressed thoughts that were considered the 
root of the mental instability [2].
 
On the order hand, Freud's detractors found in the biological 
model, the explanation of many mental illness. They stand that 
mental health problems were caused by biochemical imbalances 
proposing psychosurgery or electroconvulsive therapy to treat 
mental health imbalances. 
These beliefs also opened the door to psychopharmacology options. 
In this area, drugs like chloral hydrate, bromides, barbiturates 
and specially lithium proved to be effective in controlling the 
symptoms of many mental problems [3].
In the following decades of 20th century other drugs like 
chlorpromazine, diazepam or fluoxetine became the most 
prescribed drugs for certain mental disorders.
In this 21st century, brand new drugs were developped and are now 
available in the pharmaceutical market. It is a fact that rather than 
replacements, these new pharmacological options are constantly 
added to the old therapeutical arsenal in order to treat currently 
mental disorders. 
For all these reasons, mental illness treatment over the centuries, 
reflexs the complexity of the therapy adopted by health systems 
along the history. The challenge is to know if these changes have 
had a positive impact on these patients.
To contribute to clarify this topic, the present study was carried 
out, namely, in order to determine whether the changes in 
pharmacological therapy that have occurred over the last decades 




This is a retrospective-descriptive study with an analytical stage in 
which clinical histories of patients admitted to the Mental Health 




Primary source based on the Clinical Histories of patient 
hospitalization in a Mental Institution of Private Management 
of the City of La Plata, Buenos Aires, Argentina. The medical 
records of each decade were selected by simple random probability 
sampling, stratifying the sample according to each of the decades 
included in the study (from 1950 to 2020). The sample size was 30 
medical records for each 10-year period.
Tools for Data Collection
Database created especially for the study.
Variables
The variables analyzed in this study were: age, sex, diagnosis, 
average stay in hospital, number and reason for re-hospitalizations, 
quantity and type of medications prescribed and administered 
per decade, results obtained in terms of clinical improvement of 
patients treated, side effects associated to treatment, cost related 
to the drugs administered and overall cost for each hospitalization 
in each decade (taken at current costs adjusted current values with 
inflation data). Cost of the medicines was considered as defined by 
the daily dose (DDD) for each patient treated.
Statistical analysis
The statistical analysis was performed with the EPI INFO 7.0 
statistical software, each variable was coded for the programme 
management, with its description and its categories. This 
programme allows expressing the results in frequency and 
percentage of each study variable.
Ethical aspects
This work was carried out according to international standards for 
biomedical research in human beings proposed by the Scientific 
Reasearch Commission (CIC Nº02-18). 
Results
Two hundred and ten medical records were included in the analysis 
(52.8% were females and 47.2% were males). The average age of 
the patient’s record enrolled in the study was 60.6 ± 8.1 years.
The type of mental health pathologies that needed hospitalization 
were evaluated along the different decades. The overall prevalence 
of these diagnoses remained stable over time: schizophrenia 
(14.47%), psychosis (23.68%), bipolar disorder (13.15%), 
dementia and depression (10.52%), among other pathologies. It 
should be noted that in the last decade analyzed, in 27.7% of the 
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cases, diagnoses at hospital admission were associated with an 
addiction (dual pathology) 
It was established that the average length of hospital stay 
was 6.33±3.4 months, with a mean number of 3.18±1.9 re-
hospitalizations in each patient. Starting in the 21st century, there 
was a reduction in patient’s age (55.21 ± 9.3 years); in length of 
hospitalization time (4.66±2.7 months). It was also seen an increase 
in the number of re-hospitalizations (4.3±2.2 re-hospitalizations / 
patient).
The average number of drugs administrated was 5.14 ± 2.3 / patient 
(1.6 ± 0.9 in the 1950s and 7.22 ± 3.9 today).
The therapeutic impact achieved with the treatment provided 
in each decade was also determined in terms of pre-established 
indicators such as the average in-patient stay measured in 
months, number of re-hospitalizations and the degree of clinical 
improvement achieved. We also registered all treatments 
administered, focusing on the number and type of drugs prescribed 
per decade and the costs associated with these pharmacological 
therapies administrated. These results showed that during the 
1950s, the most prescribed drugs were lithium and chlorpromazine, 
in the 1960s haloperidol; in the '70s benzodiazepines (BZD), 
haloperidol, in the ‘80s amitriptyline was added; in the ‘90s 
fluoxetine, sertraline, haloperidol and BZD; in 2000, risperidone, 
paroxetine and pregabalin were added; and from 2010 to 2020, new 
antipsychotics (olanzapine, ziprasidone, quetiapine or lurasidone), 
antiepileptics (lamotrigine) were incorporated to the therapeutical 
options (Figure 1).
Regarding adverse effects, these events were recorded for each 
decade in a global way (including extrapyramidal signs, arterial 
hypotension, electrocardiographic alterations, laboratory changes, 
weight gain, or discontinuation of treatment) detecting a slight 
decrease, although without being statistically significant, in the 
last two decades (76.6% of the patients in the ‘50s; 73.3% in the 
‘60s, and ‘70s, 70.0% in the 80s, 66.6% in the ‘90s; 63.3% in 2000 
and in 2010).
In relation to costs, an adjustment of each price to current value 
was performed. It was observed an increase in more than 9 times 
the cost associated drug’s prices during hospitalization along 
the decades (Figure 2), and also an increase in 4 times the cost 
of hospitalization in the last decade compared to the 21th century 
(Figure 3).
Discussion
Mental diseases are identified and described in the “Diagnostic 
and Statistical Manual of Mental Disorders” (DSM). At least 15 
new diagnoses were included in this DSM Manual during the last 
two decades.
Current times have pushed us to medicalize some aspects of our 
life to the point that “Internet gaming disorder” is now part a 
clinical diagnosis included in the list of mental diseases registered 
in the DSM.
However, those severe mental health disorders that need 
hospitalization remained quite stable over decades as we 
demonstrated in this study. Perhaps some diagnostic criteria have 
been modified, but the pathologies basically stand without changes. 
Noteworthly, it should be noted that in the last decades dual pathology 
increased, that is, an addiction (to illicit or licit drugs) accompanies 
the classical diseases that required hospital admission.
Figure 1: Drugs used during hospitalization over the decades according to order of appearance.
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On the other hand, the use of drugs mental health problems treatment 
varied from 1950 to 2020. It is interesting to remark that novel 
drugs presented in the pharmaceutical market are later installed as 
valid therapeutic options for mental illnesses in doctor’s cabinets, 
however that new option did not replace previous treatments but 
rather add to the old therapeutic arsenal.
Lithium was one of the first drugs widely used to treat psychiatric 
patients with acute mania or affective psychosis [4]. Later, 
the appearance of chlorpromazine did not provide differences 
with lithium to control typical manic symptoms [5], nor did 
benzodiazepines [6] to achieve behaviour modifications, but 
all these pharmacological groups remained available as ancient 
alternatives at the same time. 
The scientific research in the 60’s contributed with a better 
understanding of mental disease and added antipsychotic drugs 
like haloperidol which affects the dopaminergic system as 
chlorpromazine did, having both medicines a potential role in 
diseases such as schizophrenia or psychosis [7].
The same occurred in the 70’s with monoaminooxidase (MAO) 
pathway or the serotonergic system in the 90’s in depression 
treatment [8], with a relevant role for MAO inhibition with 
amitriptylin or for selective serotonin reuptake inhibitors (SSRIs) 
such as fluoxetine, that are both still available today [9].
In other words, in this 21st century, there are several therapeutic 
options for mental disorders treatment, some of those drugs have 
70 years old and others were recently included in the market. 
Figure 2: Cost associated to pharmacological treatment drugs over the last decades.
















Figure 3: Hospital monetary charges (excluding pharmacological treatment).
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What is relevant is that according to our study, the efficacy in 
terms of days spent in hospital or number of re-hospitalizations, no 
improvement have seen over decades, not matter what treatment 
patient’s have recieved.
It is true that the side effects associated with the use of old drugs 
have been reduced with the new options. If the number of medical 
records in the study would been greater, probably the difference 
between old and new therapeutic options could have been 
statistically significant. However, it is also fair to recognize that the 
cost of these innovative drugs are extremely high for the benefits 
associated to their used, aspects that should be take into account 
specially in low income countries. In this study the cost of the new 
drugs included during the last two decades, increased 9 times in 
relation to the old ones, (i.e. typical versus new antipsychotics) 
without obtaining a significantly impact in terms cost/effectiveness 
ratio [10-13]. 
It is clear that the present study has limitations. It is fair to accept 
that there are many aspects that vary from decade to decade, 
and that were not considered in the analysis. It is also true that 
the effectiveness in terms of re-entry to family or return to work 
activities, is an important data not included because not all medical 
records had this data. We are also aware of the limitations of side 
effects analysis, since it was done globally, without discriminating 
between mild and severe effects, or comparing each therapeutic 
group with each other.
Our intention was just to put in evidence the poor results that 
pharmacological therapies have had for the treatment of mental 
health problems over the years, compared to other diseases like 
cardiac illness (i.e. mortality before and after bypass or stenting 
techniques); or infectious disease (mortality when only penicillins 
and sulfa existed at current deaths). Clearly there are branches of 
medicine that have advanced more than others, and among the 
latter examples are pharmacological options for mental disorders.
Conclussion
This case-study shows that even when therapeutical options for 
mental disorders exponentially increased in the last decades, 
effectiveness of pharmacological treatments (in terms of length 
of hospitalization and in the average number of hospital re-
admissions per patient) have not changed substantially during the 
last 70 years, while during that period of time, the costs of these 
same drugs have increased 9 times.
References
1. Foerschner AM. The History of Mental Illness: From Skull 




3. Jutras M. Historical perspectives on the theories, diagnosis, 
and treatment of mental illness. BCMJ. 2017; 59: 86-88.
4. Judd LL, Hubbard B, Janowsky DS, et al. The effect of lithium 
carbonate on affect, mood, and personality of normal subjects. 
Arch Gen Psychiatry. 1977; 34: 346-351.
5. Braden W, Fink EB, Qualls CB, et al. Lithium and 
chlorpromazine in psychotic inpatients. Psychiatry Res. 1982; 
7: 69-81.
6. Chouinard G. The use of benzodiazepines in the treatment of 
manic-depressive illness. J Clin Psychiatry. 1988; 49: 15-20.
7. Kendler KS, Schaffner KF. The dopamine hypothesis of 
schizophrenia. An historical and philosophical analysis. Philos 
Psychiatr Psychol. 2011; 18: 41-63.
8. Moncrieff J, Cohen D. Do antidepressants cure or create 
abnormal brain states? PLoS Med. 2006; 3: e240.
9. Murphy FC, Smith KA, Cowen PJ, et al. The effects of 
tryptophan depletion on cognitive and affective processing in 
healthy volunteers. Psychopharmacology. 2002; 63: 42-53.
10. Suttajit S, Srisurapanont M, Xia J, et al. Quetiapine versus 
typical antipsychotic medications for schizophrenia. Cochrane 
Database of Systematic Reviews. 2013; 5: CD007815.
11. Burry L, Mehta S, Perreault MM, et al. Antipsychotics for 
treatment of delirium in hospitalised non-ICU patients. 
Cochrane Database of Systematic Reviews. 2018; 6: 
CD005594.
12. Samara MT, Klupp E, Helfer B, et al. Increasing antipsychotic 
dose versus switching antipsychotic for non response in 
schizophrenia. Cochrane Database of Systematic Reviews. 
2018; 5: CD011884.
13. Uçok A, Gaebel W. Side effects of atypical antipsychotics: a 
brief overview. World Psychiatry. 2008; 7: 58-62.
© 2020 Marin G. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License
